Rationale: Portopulmonary hypertension (PPHTN) occurs in 6% of liver transplant candidates. The pathogenesis of this complication of portal hypertension is poorly understood. Objectives: To identify genetic risk factors for PPHTN in patients with advanced liver disease. Methods: We performed a multicenter case-control study of patients with portal hypertension. Cases had a mean pulmonary artery pressure .25 mm Hg, pulmonary vascular resistance .240 dynesÁs 21 Ácm 25 , and pulmonary capillary wedge pressure <15 mm Hg. Controls had a right ventricular systolic pressure , 40 mm Hg (if estimated) and normal right-sided cardiac morphology by transthoracic echocardiography. We genotyped 1,079 common single nucleotide polymorphisms (SNPs) in 93 candidate genes in each patient. Measurements and Main Results: The study sample included 31 cases and 104 controls. Twenty-nine SNPs in 15 candidate genes were associated with the risk of PPHTN (P , 0.05). Multiple SNPs in the genes coding for estrogen receptor 1, aromatase, phosphodiesterase 5, angiopoietin 1, and calcium binding protein A4 were associated with the risk of PPHTN. The biological relevance of one of the aromatase SNPs was supported by an association with plasma estradiol levels. Conclusions: Genetic variation in estrogen signaling and cell growth regulators is associated with the risk of PPHTN. These biologic pathways may elucidate the mechanism for the development of PPHTN in certain patients with severe liver disease.
Pulmonary arterial hypertension (PAH) is characterized by elevated pulmonary artery pressure and pulmonary vascular resistance, right heart failure, exercise limitation, and an increased risk of death. Histopathologic examination reveals intimal proliferation, medial hypertrophy, and adventitial fibrosis in the small muscular pulmonary arteries. Plexiform lesions and in situ thrombosis are also seen. Most commonly idiopathic, PAH may also be associated with portal hypertension, termed portopulmonary hypertension (PPHTN). McDonnell and colleagues showed a prevalence of histopathologic changes of PAH of 0.61% in autopsies of patients with cirrhosis, and PPHTN was the third most common form of PAH in a population-based epidemiologic study in France (1, 2) . Recent cohort studies showed that the prevalence of PPHTN in patients presenting for liver transplant evaluation is between 5 and 6% (3) (4) (5) . Patients with PPHTN have an increased risk of death, even with specific PAH treatment (4, (6) (7) (8) . In many cases, PPHTN greatly complicates or precludes liver transplantation, significantly affecting the course of hepatic failure in these patients (6, 9, 10) .
The etiology of PAH in patients with portal hypertension (characterized by systemic vasodilatation) is unclear. We have shown that female sex and type of liver disease are associated with the risk of PPHTN (11) . Although germline mutations in the gene that codes for bone morphogenetic protein receptor type II (BMPR2) have been associated with idiopathic and familial forms of PAH, they have not been found in patients with PPHTN (12) . Genetic variation in the serotonin transporter (SERT) has been associated with the risk of PAH in some studies (13) but not in others (14, 15) . We did not find an association between genetic variation at SERT loci and the risk of PPHTN (16) .
We therefore hypothesized that variation in genes other than BMPR2 and SERT contribute to the risk of developing PPHTN. We performed a high-throughput candidate gene study in an attempt to identify common genetic variation associated with the risk of PPHTN in a group of patients undergoing liver transplantation evaluation. This work has been previously published in abstract form (17) .
METHODS Study Cohort and Study Sample
The Pulmonary Vascular Complications of Liver Disease (PVCLD) Study enrolled a cohort of 536 patients evaluated for liver transplantation or pulmonary hypertension at seven centers in the United States between 2003 and 2006. The only inclusion criterion was the presence of chronic portal hypertension with or without intrinsic liver disease. We excluded patients with evidence of active infection, recent (,2 wk) gastrointestinal bleeding, or who had undergone liver or lung transplantation. The institutional review boards at each of the participating centers approved this study, and informed consent was obtained.
We performed a case-control study. The study sample included newly referred patients who were evaluated with transthoracic echocardiography (routinely performed for pretransplant evaluation) during the study period. ''Prevalent'' patients who met the case definition (see below) were also included. We excluded patients with pulmonary function testing showing a significant obstructive or restrictive ventilatory defect (see online supplement). We also excluded patients with HIV infection or the presence of more than moderate aortic or mitral valvular disease or significant left ventricular dysfunction by transthoracic echocardiography.
Case and Control Definitions
Cases with PPHTN met the following criteria at initial evaluation: (1) mean pulmonary artery pressure . 25 mm Hg, pulmonary capillary wedge pressure (or left ventricular end-diastolic pressure) < 15 mm Hg, and pulmonary vascular resistance .240 dynesÁs 21 Ácm 25 measured by right heart catheterization; and (2) no other etiology for pulmonary hypertension. Controls met the following echocardiographic criteria at entry into the cohort: (1) right ventricular systolic pressure , 40 mm Hg (if estimable), and (2) absence of right atrial or ventricular dilation, hypertrophy, or dysfunction. Prevalent cases who had previously undergone evaluation and were subsequently being treated were also included.
Clinical Variables and Blood Sampling
Data were collected from subjects and the medical record. The Model for End-stage Liver Disease (MELD) score was calculated (18) . Phlebotomy was performed and blood was collected into EDTAcontaining tubes. Plasma and buffy coat layers were stored at 2808C.
Candidate Genes and Single Nucleotide Polymorphism Selection
Ninety-three genes affecting vascular function were selected by the investigators (Table 1) . For this study, 1,079 single nucleotide polymorphisms (SNPs) in the 93 candidate genes were genotyped (see Table  E1 in the online supplement). We genotyped an additional set of 60 SNPs (null loci) from a validated list of Ancestry Informative Markers (19) to detect potential population stratification. (See online supplement for details of gene and SNP selection.)
Genotyping
Genomic DNA was isolated from peripheral leukocytes using standard procedures (Gentra Puregene; Qiagen, Valencia, CA). SNP genotyping was performed using the GoldenGate Assay (Illumina, Inc., San Diego, CA).
Statistical Analysis
Continuous data were summarized using mean 6 standard deviation or median (interquartile range), as appropriate. Categorical variables were summarized using n (%). Unpaired Student t tests, Wilcoxon rank sum tests, chi-square tests, and Fisher exact tests were used, as appropriate.
Hardy-Weinberg equilibrium (HWE) was assessed for genetic alleles using Fisher exact tests in controls. The association of genotype with case/control status was assessed using additive models in multivariate logistic regression and expressed with odds ratios (ORs). We adjusted for sex and autoimmune liver disease (previously associated with case status [11] ) in the final multivariate logistic regression models. Because the main goal of this study was hypothesis generation, adjustment for multiple comparisons was not performed. Single locus association analyses were performed using SAS/STAT (SAS Institute, Cary, NC).
For genes in which more than one SNP was associated with PPHTN, we determined haplotype structure and pairwise linkage disequilibrium between SNPs using Haploview 4.0 (20) . The presence or absence of population stratification was assessed by comparing allele frequencies of the 60 null loci between cases and controls using chi-square tests (21) . Sensitivity analyses assessed the potential impact of racial differences or cryptic subpopulations. P , 0.05 was considered significant for all analyses.
There was 80% power to detect odds ratios of >2.4 to 4.0 (or <0.25 to 0.42), depending on the minor allele frequency of the SNP (range, 0.45-0.05). Power analysis was performed using QUANTO 1.2 (22) .
RESULTS
There were 31 cases and 104 controls. The mean age of the subjects was 52 6 10 years, and 60 (44%) were female. One hundred and twenty-one (90%) were white and seven (5%) were black. Sixteen (13%) of the white subjects were of Hispanic ethnicity (12% of the study sample). Subjects with PPHTN had a mean right atrial pressure of 10 6 6 mm Hg (n 5 30), a mean pulmonary artery pressure of 50 6 9 mm Hg, and pulmonary capillary wedge pressure (or left-ventricular end-diastolic pressure) of 10 6 4 mm Hg. The cardiac output was 5.5 6 1.8 L/min, the cardiac index was 2.9 6 0.9 L/min/m 2 , and the pulmonary vascular resistance was 672 6 374 dynesÁs 21 Ácm 25 .
Bivariate Analyses
Age, race, and severity of liver disease were similar between the groups (Table 2) . Female sex and autoimmune hepatitis were associated with an increased risk for PPHTN, as previously reported in this population (11) . One case and one control had a-1 antitrypsin deficiency, one control had biliary atresia, one case had sarcoid, and one case had portal vein thrombosis.
Genetic Analyses
Nine hundred and ninety-three (of the 1,079) SNPs conformed to HWE in controls (P . 0.05) and were included in the analysis. Twenty-nine SNPs in 15 genes were significantly associated with PPHTN after adjustment for sex and liver disease etiology (autoimmune hepatitis) ( Table 3 ). In the gene coding for estrogen receptor 1 (ESR1), 7 of 36 SNPs were associated with either a significantly decreased (OR 5 0.39-0.18) or increased (OR 5 2.56-2.70) risk of PPHTN. The five protective SNPs included four intronic and one synonymous Exon 4 SNP (rs1801132, P324P). Pairwise linkage disequilibrium analyses demonstrated that these five loci represented a single haplotype block (D9 5 0.71-0.84) (Table E2 and Figure E1 ). Distal to these protective loci, two SNPs (rs7757956 and rs3020368, D9 5 0.89) were associated with an increased risk of PPHTN. Two promoter SNPs in the gene coding for aromatase (CYP19A1), the ratelimiting enzyme in the conversion of the androgens testosterone and androstenedione to estradiol, were associated with an increased risk of PPHTN (Tables 3 and E2 , Figure E2 ).
Four of nine SNPs genotyped in phosphodiesterase 5 (PDE5A) were in tight linkage disequilibrium (r 2 5 0.95-1.00) (Table E2 ) and all were associated with an increased risk of PPHTN (all OR 5 2.11; 95%CI, 1.05-4.22; P 5 0.03) ( Table 3) . Two tightly linked SMAD3 intron 1 SNPs (rs4776881 and rs12324036, r 2 . 0.97) were associated with a decreased risk of PPHTN (both OR 5 0.50; 95%CI, 0.26-0.95; P 5 0.035). Two SNPs in each of three genes-calcium binding protein A4 (S100A4), angiopoietin 1 (ANGPT1), and retinoic acid receptor, b (RARB)-were associated with case status and were not in linkage disequilibrium (Tables 3 and E2 , Figure E3 ). Of note, polymorphisms in BMPR2 or genes coding for bone morphogenetic protein receptor Type Ia (BMPR1A), activin A receptor type II-like 1 (ACVRL1), or endoglin (ENG) were not associated with PPHTN. There were no significant differences in allele frequencies of the 60 null alleles between cases and controls (all P . 0.05), lessening the chance of population stratification. We assessed for potential confounding by liver disease etiology (other than autoimmune hepatitis). Eight SNPs associated with PPHTN were also independently associated with various liver disease etiologies; in all cases, adjustment for liver disease etiology resulted in either no significant change or strengthening of the association between the SNP and case status (Table E3) .
There were no significant differences in the results from the main analyses and results of analyses performed in females only (n 5 60), self-identified whites (n 5 121), and subjects with white genetic ancestry (n 5 124) (data not shown), indicating that neither sex nor race (nor genetic ancestry-based) differences accounted for our results.
Plasma Estradiol
Estradiol levels were measured in 28 cases and 98 controls with available plasma (see online supplement for assay details). Estradiol levels increased in a dose-dependent fashion with the A allele of the aromatase rs7175922 SNP (the allele associated with an increased risk of PPHTN), even after adjustment for sex (Figure 1 ). Estradiol levels were not associated with genotypes of the other aromatase SNP associated with case status (data not shown).
DISCUSSION
This is the first study to document genetic risk factors for PPHTN. Using a high-throughput candidate gene approach, we found SNPs in a variety of genes that were associated with the development of PAH in patients with advanced liver disease. Pathways with multiple gene ''hits'' included estrogen signaling, cellular growth/apoptosis, and oxidative stress. Other SNPs associated with case status included those in genes coding for recombination signal-binding protein 1 for J-kappa (RBPSUH), inducible nitric oxide synthase (NOS2A), and plasminogen activator inhibitor-1 (SERPINE1 or PAI-1). A number of the genes and signaling pathways found here have also been implicated in human or experimental PAH, supporting the concept that there may be shared pathogenetic mechanisms. In addition, several novel associations have been shown that may provide important mechanistic and therapeutic insights.
The role of estrogen signaling and increased estradiol levels in the pathogenesis of PAH and PPHTN has not been defined. PPHTN (like idiopathic and familial PAH) affects females more commonly than males (11) , an association that may be related to a high estrogen state. However, estrogen has traditionally been Definition of abbreviations: Chr 5 chromosome; RefSeq 5 Reference Sequence; SNP 5 single-nucleotide polymorphism. * Indicates adjacent genes that were defined by a single genomic region and tagging SNPs. Thus the number of SNPs indicated refers to the total number of SNPs assayed in the region containing both genes. believed to play a protective role in the systemic and pulmonary vasculature, modulating proliferative and vasoactive signaling by direct and receptor-mediated mechanisms (23, 24) . In animal models of pulmonary hypertension, estrogen increases nitric oxide and prostacyclin production and decreases endothelin-1 (25) (26) (27) , resulting in beneficial vascular effects. Such data are seemingly difficult to reconcile with studies showing adverse cardiovascular effects of estrogen. For instance, the Women's Health Initiative revealed that (despite many observational studies suggesting otherwise) hormone replacement therapy actually increased the risk for adverse cardiovascular events (28) . These apparent paradoxes may be explained by the complexity of the influence of estrogen on vascular homeostasis, resulting from variable expression of estrogen receptors 1 and 2 (a and b), cell and tissue specificity, and the influential balance between estrogen and other steroid hormones, such as testosterone and progesterone (29) (30) (31) . We found that genetic variation in both the estrogen receptor 1 and aromatase (the rate-limiting enzyme in the conversion of androgens to estrogens) was associated with the risk of PPHTN, independent of sex. The two aromatase SNPs (rs1902584 and rs7175922) are located in the 93-kb region upstream (59) of exon 2, where numerous tissue-specific promoters reside and thus could differentially influence aromatase expression in tissues (32) . Furthermore, the association between the high-risk aromatase allele (rs7175922) and increased estradiol levels supports a functional effect of this SNP. Together, these findings strongly implicate estrogen signaling in the pathogenesis of PPHTN and define specific putative genetic factors that may contribute.
Several of the genes identified in our study participate in the regulation of cellular growth and apoptosis and have been implicated in human PAH and/or animal models of PAH. For example, we found that variation in PDE5A, which codes for a key enzyme in cyclic guanine monophosphate (cGMP) metabolism, was associated with PPHTN. Phosphodiesterase 5 inhibitors, such as sildenafil, potentiate the antiproliferative and vasodilatory effects of cGMP and improve hemodynamic features in PPHTN and other forms of PAH (33-35). Our finding supports a role for altered cGMP production in causing disease in these patients and introduces PDE5A genotype as a potential pharmacogenomic target. We also found a relationship between genetic variability in ANGPT1 and risk of PPHTN. ANGPT1 plays a pivotal role in angiogenesis, and enhanced ANGPT1 expression or signaling has been reported to have beneficial effects in several experimental models of PAH (36) (37) (38) . Although the exact role of ANGPT1 in pulmonary hypertension remains obscure, our findings support a role for this molecule in human disease. Finally, we found an association between PPHTN and genetic variation in a SNP in S100A4, a member of a family of calciumbinding proteins involved in regulation of endothelial proliferation and adhesion (39) . S100A4 is expressed in the plexiform lesions of individuals with certain types of PAH (40) . In a murine model, overexpression of S100A4 results in increased arteriolar remodeling, plexiform lesions (41) , and pulmonary hypertension in response to hypoxia (42) . We have now found a potential causal link between S100A4 and human disease.
An additional 10 genes had SNPs associated with PPHTN. Six of these-SERPINE1, RARB (43), caveolin 1 (CAV1) (44), SMAD3, runt-related transcription factor 1 (RUNX), and RBPSUH (45)-play a significant role in angiogenesis. SERPINE1 codes for PAI-1, which modulates the proliferative and migratory properties of pulmonary artery smooth muscle cells (PASMC) and has been shown to be down-regulated in individuals with IPAH (46) . We found that genetic variation in NADPH oxidase 4 (NOX4), xanthine dehydrogenase, and superoxide dismutase 2 was associated with PPHTN. Redox signaling has recently been implicated as a potential node of control for pulmonary vascular response (47) . NOX4 localizes to the media of small pulmonary arteries and, in a hypoxic mouse model, contributes to PASMC proliferation. Pulmonary arterioles from IPAH patients demonstrate a significantly increased level of NOX4 protein, confirming a potentially important role of NOX4 overexpression in PAH (48) . Last, genetic variation in NOS2A may contribute the hypercoagulability and vasoconstriction characteristic of PPHTN. By the nature of their roles in angiogenesis, control of coagulation, and vascular tone pathways, these 10 genes offer plausible candidates for determining the risk of PPHTN.
Disruption in bone morphogenetic protein/transforming growth factor b signaling has been demonstrated in familial and idiopathic forms of PAH (49, 50) . Although we cannot rule out the possibility of a rare coding mutation in our subjects, use of regional linkage disequilibrium and haplotype-tagging SNPs makes a contribution of common genetic variation in BMPR2, BMPR1A, ACVRL1, or ENG to portopulmonary hypertension unlikely.
There are several limitations to this study. First, the sample size was small, limiting our ability to find genetic alleles associated with PPHTN that are rare, have small effect sizes, or whose effect depends on gene-gene or gene-environment interaction. However, this is one of the largest epidemiologic studies of PPHTN with very strict case and control phenotypes ever performed and the first in PAH to use high-throughput genotyping.
A fundamental challenge in high-throughput genetic analyses is the control of type I error. Given that we analyzed multiple SNPs for each of more than 90 genes, we can reasonably expect a certain number of statistically significant associations due to chance alone. We attempted to minimize the chance of false positives by using a curated candidate gene list, thus increasing the prior probability that one or more of these genes has mechanistic importance in PPHTN. There are commonly used frequentist methods to adjust for multiple comparisons in highthroughput studies, such as the Bonferroni correction and false discovery rate (51) . Both methodologies assume that the association of each individual SNP with case status is entirely independent of those of the other SNPs. We have documented patterns of linkage disequilibrium between genotyped SNPs. Because most accepted methods to account for multiple comparisons do not consider such relatedness, they are overly conservative for this purpose. We have therefore presented the results without adjustment and consider these results to be hypothesisgenerating. Although replication would be important, the biologic plausibility of our findings, the multiple gene ''hits'' in certain pathways (estrogen signaling and oxidative stress), and the demonstration of functionality (aromatase genotype and plasma estradiol levels) are reassuring in terms of the validity of the findings (52).
Our results implicate common genetic variation in the pathogenesis of PPHTN. Future studies should focus on replication in other populations and the mechanisms that explain the associations between the SNPs of interest and PPHTN.
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